Celltrion Pharm, Inc.
Celltrion Pharm, Inc., a leading biopharmaceutical company headquartered in South Korea (KR), has established itself as a key player in the global healthcare industry since its founding in 2002. With a strong focus on the development and manufacturing of biosimilars and innovative therapeutics, Celltrion operates extensively across major markets, including Europe, the United States, and Asia. The company is renowned for its core products, which include monoclonal antibodies and biosimilars that offer cost-effective alternatives to expensive biologics. Celltrion's commitment to quality and innovation has positioned it as a trusted name in the biopharmaceutical sector, achieving significant milestones such as the successful launch of its flagship biosimilar, Remsima. With a robust pipeline and a dedication to advancing healthcare solutions, Celltrion Pharm continues to make strides in improving patient outcomes worldwide.
DitchCarbon Score
How does Celltrion Pharm, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celltrion Pharm, Inc.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celltrion Pharm, Inc.'s reported carbon emissions
Celltrion Pharm, Inc., headquartered in South Korea (KR), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no documented Scope 1, 2, or 3 emissions to analyse. Furthermore, the company has not established any formal reduction targets or climate pledges, which suggests a lack of publicly available commitments towards carbon neutrality or emissions reduction initiatives. As there is no inherited emissions data from a parent or related organization, all information regarding climate commitments is based solely on the company's own disclosures. In the context of the pharmaceutical industry, it is increasingly important for companies to adopt robust climate strategies and transparent reporting practices to align with global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Celltrion Pharm, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
